Understanding uveitis: The impact of research on visual outcomes

Progress in Retinal and Eye Research

Volumn 30, Issue 6, 2011, Pages 452-470

  de Smet, Marc D ^a,i   Taylor, Simon R J ^b,j   Bodaghi, Bahram ^c   Miserocchi, Elisabetta ^d   Murray, Philip I ^e   Pleyer, Uwe ^f   Zierhut, Manfred ^g   Barisani Asenbauer, Talin ^h   LeHoang, Phuc ^c   Lightman, Sue ^b,j  

^a Centers for Specialized Ophthalmology   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c SORBONNE UNIVERSITÉ   (France)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ UNIVERSITY OF AMSTERDAM   (Netherlands)

^j MOORFIELDS EYE HOSPITAL   (United Kingdom)

more..

Author keywords

Animal models; Corticosteroids; Cytokines; Epidemiology; Immunosuppressive agents; Socioeconomics; Uveitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BEVACIZUMAB; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTOKINE; DEXAMETHASONE; ETANERCEPT; FLUOCINOLONE ACETONIDE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; RITUXIMAB; STEROID; TRIAMCINOLONE;

DEMYELINATING DISEASE; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE CONTROL; DNA POLYMORPHISM; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RETINA MACULA EDEMA; REVIEW; SOCIOECONOMICS; T LYMPHOCYTE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UVEITIS;

AGE FACTORS; ANIMALS; BIOMEDICAL RESEARCH; EPIDEMIOLOGIC STUDIES; HUMANS; MODELS, ANIMAL; QUALITY OF LIFE; SOCIOECONOMIC FACTORS; UVEITIS;

EID: 80054703288     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2011.06.005     Document Type: Review

References (311)

1. Abu El-Asrar A.M., Struyf S., Descamps F.J., Al-Obeidan S.A., Proost P., Van Damme J., Opdenakker G., Geboes K. Chemokines and gelatinases in the aqueous humor of patients with active uveitis. Am. J. Ophthalmol. 2004, 138:401-411.
2. Ahn J.K., Yu H.G., Chung H., Park Y.G. Intraocular cytokine environment in active Behcet uveitis. Am. J. Ophthalmol. 2006, 142:429-434.
3. Albuquerque M.C., Aleixo A.L., Benchimol E.I., Leandro A.C., das Neves L.B., Vicente R.T., Bonecini-Almeida Mda G., Amendoeira M.R. The IFN-gamma +874T/A gene polymorphism is associated with retinochoroiditis toxoplasmosis susceptibility. Mem. Inst. Oswaldo Cruz. 2009, 104:451-455. PMID: 19547871.
4. Angeles-Han S.T., Griffin K.W., Lehman T.J., Rutledge J.R., Lyman S., Nguyen J.T., Harrison M.J. The importance of visual function in the quality of life of children with uveitis. J. AAPOS 2010, 14:163-168.
5. Anglade E., Aspeslet L.J., Weiss S.L. A new agent for the treatment of noninfectious uveitis: rationale and design of three LUMINATE (Lux Uveitis Multicenter Investigation of a New Approach to Treatment) trials of steroid-sparing voclosporin. Clin. Ophthalmol. 2008, 2:693-702.
6. Antcliff R.J., Spalton D.J., Stanford M.R., Graham E.M., ffytche T.J., Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001, 108:765-772.
7. Atan D., Fraser-Bell S., Plskova J., Kuffova L., Hogan A., Tufail A., Kilmartin D.J., Forrester J.V., Bidwell J., Dick A.D., Churchill A.J. Cytokine polymorphism in noninfectious uveitis. Invest. Ophthalmol. Vis. Sci. 2010, 51:4133-4142.
8. Atkins D., Best D., Briss P.A., Eccles M., Falck-Ytter Y., Flottorp S., Guyatt G.H., Harbour R.T., Haugh M.C., Henry D., Hill S., Jaeschke R., Leng G., Liberati A., Magrini N., Mason J., Middleton P., Mrukowicz J., O'Connell D., Oxman A.D., Phillips B., Schunemann H.J., Edejer T.T., Varonen H., Vist G.E., Williams J.W., Zaza S. Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490.
9. Bailey T.A., Kanuga N., Romero I.A., Greenwood J., Luthert P.J., Cheetham M.E. Oxidative stress affects the junctional integrity of retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2004, 45:675-684.
10. Baranano D.E., Kim S.J., Edelhauser H.F., Durairaj C., Kompella U.B., Handa J.T. Efficacy and pharmacokinetics of intravitreal non-steroidal anti-inflammatory drugs for intraocular inflammation. Br. J. Ophthalmol. 2009, 93:1387-1390.
11. Barisani-Asenbauer T. Monitoring treatment with biologics in non-infectious uveitis. Ophthalmologe 2011, 108:21-24.
12. Barry R.J., Murray P.I. Unregistered visual impairment: is registration a failing system?. Br. J. Ophthalmol. 2005, 89:995-998.
13. Becker M., Davis J. Vitrectomy in the treatment of uveitis. Am. J. Ophthalmol. 2005, 140:1096-1105.
14. Becker M.D., Wertheim M.S., Smith J.R., Rosenbaum J.T. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul. Immunol. Inflamm. 2005, 13:289-293.
15. BenEzra D. Clinical aspects and diagnostic guidelines of ocular Behcet's disease. Dev. Ophthalmol. 1999, 31:109-117.
16. BenEzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2005, 89:444-448.
17. Berger-Schoch A.E., Herrmann D.C., Schares G., Muller N., Bernet D., Gottstein B., Frey C.F. Prevalence and genotypes of Toxoplasma gondii in feline faeces (oocysts) and meat from sheep, cattle and pigs in Switzerland. Vet. Parasitol. 2011, 177:290-297.
18. Berry D.A. Adaptive clinical trials: the promise and the caution. J. Clin. Oncol. 2011, 29:606-609.
19. Berry D.A., Eick S.G. Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat. Med. 1995, 14:231-246.
20. Birnbaum M.H. Bayesian Calculator 2011.
21. Birnbaum A.D., Oh F., Sahin O., Little D.M., Tessler H.H., Goldstein D.A. Chlorambucil and malignancy. Ophthalmology 2010, 117:1466.
22. Bloch-Michel E., Nussenblatt R.B. International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. Am. J. Ophthalmol. 1987, 103:234-235.
23. Bodaghi B., Cassoux N., Wechsler B., Hannouche D., Fardeau C., Papo T., Huong D.L., Piette J.C., LeHoang P. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) 2001, 80:263-270.
24. Brar M., Yuson R., Kozak I., Mojana F., Cheng L., Bartsch D.U., Oster S.F., Freeman W.R. Correlation between morphologic features on spectral-domain optical coherence tomography and angiographic leakage patterns in macular edema. Retina 2010, 30:383-389.
25. Broekhuyse R.M., Kuhlmann E.D., Winkens H.J. Experimental autoimmune anterior uveitis (EAAU): induction by melanin antigen and suppression by various treatments. Pigment Cell Res. 1993, 6:1-6.
26. Brown M.M., Brown G.C., Sharma S., Stein J.D., Roth Z., Campanella J., Beauchamp G.R. The burden of age-related macular degeneration: a value-based analysis. Curr. Opin. Ophthalmol. 2006, 17:257-266.
27. Bruce I.N. Re-evaluation of biologic therapies in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2010, 22:273-277.
28. Bruce B., Fries J.F. The Stanford health assessment questionnaire: a review of its history, issues, progress, and documentation. J. Rheumatol. 2003, 30:167-178.
29. Burmedi D., Becker S., Heyl V., Wahl H.W., Himmelsbach Emotional and social consequences of age-related low vision: a narrative review. Partial Sight Blindness Res. 2002, 4:47-71.
30. Caspi R.R. Ocular autoimmunity: the price of privilege?. Immunol. Rev. 2006, 213:23-35.
31. Callanan D.G., Jaffe G.J., Martin D.F., Pearson P.A., Comstock T.L. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch. Ophthalmol. 2008, 126:1191-1201.
32. Caspi R.R. A look at autoimmunity and inflammation in the eye. J. Clin. Invest. 2010, 120:3073-3083.
33. Caspi R.R., Roberge F.G., McAllister C.G., el-Saied M., Kuwabara T., Gery I., Hanna E., Nussenblatt R.B. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J. Immunol. 1986, 136:928-933.
34. Caspi R.R., Roberge F.G., Chan C.C., Wiggert B., Chader G.J., Rozenszajn L.A., Lando Z., Nussenblatt R.B. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 1988, 140:1490-1495.
35. Caspi R.R., Silver P.B., Luger D., Tang J., Cortes L.M., Pennesi G., Mattapallil M.J., Chan C.C. Mouse models of experimental autoimmune uveitis. Ophthalmic Res. 2008, 40:169-174.
36. Cassoux N., Giron A., Bodaghi B., Tran T.H., Baudet S., Davy F., Chan C.C., Lehoang P., Merle-Beral H. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma. Invest. Ophthalmol. Vis. Sci. 2007, 48:3253-3259.
37. Centre, T.H.a.S.C.I., 2008. Registered Blind and Partially Sighted People Year ending 31 March 2008 England.
38. Chan C.C., Palestine A.G., Nussenblatt R.B. Cyclosporine-induced alterations of humoral response in experimental autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 1984, 25:867-870.
39. Chang J.H., Wakefield D. Uveitis: a global perspective. Ocul. Immunol. Inflamm. 2002, 10:263-279.
40. Chatzistefanou K., Markomichelakis N.N., Christen W., Soheilian M., Foster C.S. Characteristics of uveitis presenting for the first time in the elderly. Ophthalmology 1998, 105:347-352.
41. Chiang Y.P., Bassi L.J., Javitt J.C. Federal budgetary costs of blindness. Milbank Q. 1992, 70:319-340.
42. Cimino L., Boiardi L., Aldigeri R., Casali B., Nicoli D., Farnetti E., Salvarani C., Cirone D., De Martino L., Pupino A., Cappuccini L. G/R 241 polymorphism of intercellular adhesion molecule 1 (ICAM-1) is associated with Fuchs uveitis. Invest. Ophthalmol. Vis. Sci. 2010, 51:4447-4450. PMID: 20445114.
43. Cordeiro C.A., Moreira P.R., Costa G.C., Dutra W.O., Campos W.R., Orefice F., Teixeira A.L. Interleukin-1 gene polymorphisms and toxoplasmic retinochoroiditis. Mol. Vis. 2008, 14:1845-1849.
44. Cordeiro C.A., Moreira P.R., Andrade M.S., Dutra W.O., Campos W.R., Oréfice F., Teixeira A.L. Interleukin-10 gene polymorphism (-1082G/A) is associated with toxoplasmic retinochoroiditis. Invest. Ophthalmol. Vis. Sci. 2008, 49:1979-1982. PMID: 18436829.
45. Cousins S.W., Guss R.B., Howes E.L., Rosenbaum J.T. Endotoxin-induced uveitis in the rat: observations on altered vascular permeability, clinical findings, and histology. Exp. Eye Res. 1984, 39:665-676.
46. Couto C.G., Merlo J.L. Epidemiological study of patients with uveitis in Buenos Aires, Argentina. Third International Symposium on Uveitis 1992, 171-174. Kugler Pub, Brussels, Belgium.
47. Covert D., Berdeaux G., Mitchell J., Bradley C., Barnes R. Quality of life and health economic assessments of age-related macular degeneration. Surv. Ophthalmol. 2007, 52(Suppl. 1):S20-S25.
48. Cunningham E.T. Exogenous factors influencing endogenous inflammation: what can patients do to improve control of their own uveitis?. Br. J. Ophthalmol. 2010, 94:813-814.
49. Cunningham E.T., Suhler E.B. Childhood uveitis-young patients, old problems, new perspectives. J. AAPOS 2008, 12:537-538.
50. Cunningham M.A., Austin B.A., Li Z., Liu B., Yeh S., Chan C.C., Anglade E., Velagaleti P., Nussenblatt R.B. LX211 (voclosporin) suppresses experimental uveitis and inhibits human T cells. Invest. Ophthalmol. Vis. Sci. 2009, 50:249-255.
51. Damsker J.M., Hansen A.M., Caspi R.R. Th1 and Th17 cells: adversaries and collaborators. Ann. N. Y. Acad. Sci. 2010, 1183:211-221.
52. Dandona L., Dandona R., John R.K., McCarty C.A., Rao G.N. Population based assessment of uveitis in an urban population in southern India. Br. J. Ophthalmol. 2000, 84:706-709.
53. Daniel E., Thorne J.E., Newcomb C.W., Pujari S.S., Kacmaz R.O., Levy-Clarke G.A., Nussenblatt R.B., Rosenbaum J.T., Suhler E.B., Foster C.S., Jabs D.A., Kempen J.H. Mycophenolate mofetil for ocular inflammation. Am. J. Ophthalmol. 2010, 149:423-432.
54. Darlington P., Tallstedt L., Padyukov L., Kockum I., Cederlund K., Eklund A., Grunewald J. HLA-DRB1* alleles and symptoms associated with Heerfordt's syndrome in sarcoidosis. Eur. Respir. J. Epub ahead of print. 2011, PMID: 21565911.
55. Darrell R.W., Wagener H.P., Kurland L.T. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch. Ophthalmol. 1962, 68:502-514.
56. Davatchi F., Shams H., Rezaipoor M., Sadeghi-Abdollahi B., Shahram F., Nadji A., Chams-Davatchi C., Akhlaghi M., Faezi T., Naderi N. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int. J. Rheum. Dis. 2010, 13:246-252.
57. Davis J.L., Madow B., Cornett J., Stratton R., Hess D., Porciatti V., Feuer W.J. Scale for photographic grading of vitreous haze in uveitis. Am. J. Ophthalmol. 2010, 150:637-641.
58. de Boer J., Wulffraat N., Rothova A. Visual loss in uveitis of childhood. Br. J. Ophthalmol. 2003, 87:879-884.
59. de Kozak Y., Sakai J., Thillaye B., Faure J.P. S antigen-induced experimental autoimmune uveo-retinitis in rats. Curr. Eye Res. 1981, 1:327-337.
60. De Kozak Y., Thillaye-Goldenberg B., Naud M.C., Da Costa A.V., Auriault C., Verwaerde C. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin. Exp. Immunol. 2002, 130:212-223.
61. de Smet M.D., Dayan M. Prospective determination of T Cell responses to S-antigen in Behçet's disease patients and controls. Invest. Ophthalmol. Vis. Sci. 2000, 41:3480-3484.
62. de Smet M.D., Nussenblatt R.B. Clinical use of cyclosporine in ocular disease. Int. Ophthalmol. Clin. 1993, 33:31-45.
63. de Smet M.D., Yamamoto J.H., Mochizuki M., Gery I., Singh V.K., Shinohara T., Wiggert B., Chader G.J., Nussenblatt R.B. Cellular immune responses of patients with uveitis to retinal antigens and their fragments. Am. J. Ophthalmol. 1990, 110:135-142.
64. de Smet M.D., Chan C.C. Regulation of ocular inflammation-what experimental and human studies have taught us. Prog. Retin. Eye Res. 2001, 20:761-797.
65. de-la-Torre A., Lopez-Castillo C.A., Rueda J.C., Mantilla R.D., Gomez-Marin J.E., Anaya J.M. Clinical patterns of uveitis in two ophthalmology centres in Bogota, Colombia. Clin. Exp. Ophthalmol. 2009, 37:458-466.
66. Deeg C.A. Ocular immunology in equine recurrent uveitis. Vet. Ophthalmol. 2008, 11(Suppl. 1):61-65.
67. Deeg C.A., Hauck S.M., Amann B., Kremmer E., Stangassinger M., Ueffing M. Major retinal autoantigens remain stably expressed during all stages of spontaneous uveitis. Mol. Immunol. 2007, 44:3291-3296.
68. Deschenes J., Murray P.I., Rao N.A., Nussenblatt R.B. International Uveitis Study Group (IUSG): clinical classification of uveitis. Ocul. Immunol. Inflamm. 2008, 16:1-2.
69. Deuter C.M., Kotter I., Gunaydin I., Stubiger N., Doycheva D.G., Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br. J. Ophthalmol. 2009, 93:906-913.
70. Deuter C.M., Zierhut M., Mohle A., Vonthein R., Stobiger N., Kotter I. Long-term remission after cessation of interferon-alpha treatment in patients with severe uveitis due to Behcet's disease. Arthritis Rheum. 2010, 62:2796-2805.
71. Devereaux P.J., Anderson D.R., Gardner M.J., Putnam W., Flowerdew G.J., Brownell B.F., Nagpal S., Cox J.L. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001, 323:1218-1222.
72. Dickx V., Geens T., Deschuyffeleer T., Tyberghien L., Harkinezhad T., Beeckman D.S., Braeckman L., Vanrompay D. Chlamydophila psittaci zoonotic risk assessment in a chicken and turkey slaughterhouse. J. Clin. Microbiol. 2010, 48:3244-3250.
73. Dixon P., Coppack R. Equine recurrent uveitis. Vet. Rec. 2002, 150:556.
74. Durrani O.M., Meads C.A., Murray P.I. Uveitis: a potentially blinding disease. Ophthalmologica 2004, 218:223-236.
75. Durrani O.M., Tehrani N.N., Marr J.E., Moradi P., Stavrou P., Murray P.I. Degree, duration, and causes of visual loss in uveitis. Br. J. Ophthalmol. 2004, 88:1159-1162.
76. Edelsten C. Reconsidering treatment options in childhood uveitis. Br. J. Ophthalmol. 2007, 91:133-134.
77. Edelsten C., Reddy M.A., Stanford M.R., Graham E.M. Visual loss associated with pediatric uveitis in english primary and referral centers. Am. J. Ophthalmol. 2003, 135:676-680.
78. European Medicines Agency Methodological Issues in Confirmatory Clinical Trials with Flexiable Design and Analysis Plan 2002.
79. European Medicines Agency Methodological Issues in Confirmatory Clinical Trials with Flexible Design and Analysis Plans 2006.
80. Feldmann M., Steinman L. Design of effective immunotherapy for human autoimmunity. Nature 2005, 435:612-619.
81. Felson D.T., Smolen J.S., Wells G., Zhang B., van Tuyl L.H., Funovits J., Aletaha D., Allaart C.F., Bathon J., Bombardieri S., Brooks P., Brown A., Matucci-Cerinic M., Choi H., Combe B., de Wit M., Dougados M., Emery P., Furst D., Gomez-Reino J., Hawker G., Keystone E., Khanna D., Kirwan J., Kvien T.K., Landewe R., Listing J., Michaud K., Martin-Mola E., Montie P., Pincus T., Richards P., Siegel J.N., Simon L.S., Sokka T., Strand V., Tugwell P., Tyndall A., van der Heijde D., Verstappen S., White B., Wolfe F., Zink A., Boers M. American College of rheumatology/European League against rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis. 2011, 70:404-413.
82. Ferrante P., Ramsey A., Bunce C., Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin. Exp. Ophthalmol. 2004, 32:563-568.
83. Forrester J.V., Xu H., Kuffov L., Dick A.D., McMenamin P.G. Dendritic cell physiology and function in the eye. Immunological Rev. 2010, 234(1):282-304.
84. Fransen J., van Riel P.L. The disease activity score and the EULAR response criteria. Rheum. Dis. Clin. North Am. 2009, 35:745-757. vii-viii.
85. Frick K.D., Gower E.W., Kempen J.H., Wolff J.L. Economic impact of visual impairment and blindness in the United States. Arch. Ophthalmol. 2007, 125:544-550.
86. Frost N.A., Sparrow J.M., Durant J.S., Donovan J.L., Peters T.J., Brookes S.T. Development of a questionnaire for measurement of vision-related quality of life. Ophthalmic Epidemiol. 1998, 5:185-210.
87. Fujino Y., Mochizuki M., Chan C.C., Raber J., Kotake S., Gery I., Nussenblatt R.B. FK506 treatment of S-antigen induced uveitis in primates. Curr. Eye Res. 1991, 10:679-690.
88. Fujino Y., Li Q., Chung H., Hikita N., Nussenblatt R.B., Gery I., Chan C.C. Immunopathology of experimental autoimmune uveoretinitis in primates. Autoimmunity 1992, 13:303-309.
89. Galor A., Feuer W., Kempen J.H., Kacmaz R.O., Liesegang T.L., Suhler E.B., Foster C.S., Jabs D.A., Levy-Clarke G.A., Nussenblatt R.B., Rosenbaum J.T., Thorne J.E. Adverse effects of smoking on patients with ocular inflammation. Br. J. Ophthalmol. 2010, 94:848-853.
90. Gardiner A.M., Armstrong R.A., Dunne M.C., Murray P.I. Correlation between visual function and visual ability in patients with uveitis. Br. J. Ophthalmol. 2002, 86:993-996.
91. Gery I., Mochizuki M., Nussenblatt R.B. Retinal specific antigens and the immunopathogentic processes they provoke. Prog. Retin. Eye Res. 1986, 5:75-109.
92. Gery I., Wiggert B., Redmond T.M., Kuwabara T., Crawford M.A., Vistica B.P., Chader G.J. Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-binding protein. Invest. Ophthalmol. Vis. Sci. 1986, 27:1296-1300.
93. Gilger B.C., Salmon J.H., Yi N.Y., Barden C.A., Chandler H.L., Wendt J.A., Colitz C.M. Role of bacteria in the pathogenesis of recurrent uveitis in horses from the southeastern United States. Am. J. Vet. Res. 2008, 69:1329-1335.
94. Gilger B.C., Wilkie D.A., Clode A.B., McMullen R.J., Utter M.E., Komaromy A.M., Brooks D.E., Salmon J.H. Long-term outcome after implantation of a suprachoroidal cyclosporine drug delivery device in horses with recurrent uveitis. Vet. Ophthalmol. 2010, 13:294-300.
95. Greenwood J. The blood-retinal barrier in experimental autoimmune uveoretinitis (EAU): a review. Curr. Eye Res. 1992, (11 Suppl):25-32.
96. Greenwood J., Howes R., Lightman S. The blood-retinal barrier in experimental autoimmune uveoretinitis. Leukocyte interactions and functional damage. Lab. Invest. 1994, 70:39-52.
97. Grimes D.A., Schulz K.F. Refining clinical diagnosis with likelihood ratios. Lancet 2005, 365:1500-1505.
98. Gritz D.C., Wong I.G. Incidence and prevalence of uveitis in northern California; the Northern California epidemiology of uveitis study. Ophthalmology 2004, 111:491-500. discussion 500.
99. Guest S., Funkhouser E., Lightman S. Pars planitis: a comparison of childhood onset and adult onset disease. Clin. Exp. Ophthalmol. 2001, 29:81-84.
100. Gulati N., Forooghian F., Lieberman R., Jabs D.A. Vascular endothelial growth factor inhibition in uveitis: a systematic review. Br. J. Ophthalmol. 2011, 95:162-165.
101. Guly C.M., Forrester J.V. Investigation and management of uveitis. BMJ 2010, 341:c4976.
102. Guyatt G.H., Oxman A.D., Kunz R., Falck-Ytter Y., Vist G.E., Liberati A., Schunemann H.J. Going from evidence to recommendations. BMJ 2008, 336:1049-1051.
103. Habot-Wilner Z., Sallam A., Pacheco P.A., Do H.H., McCluskey P., Lightman S. Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur. J. Ophthalmol. 2010, 21:56-61.
104. Habot-Wilner Z., Sallam A., Roufas A., Kabasele P.M., Grigg J.R., McCluskey P., Lightman S. Periocular corticosteroid injection in the management of uveitis in children. Acta Ophthalmol. 2010, 88:e299-e304.
105. Hale S., Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 2006, 33:231-237.
106. Hamade I.H., Velum N., Tabbara K.F. Causes of uveitis at a referral center in Saudi Arabia. Ocul. Immunol. Inflamm. 2009, 17:11-16.
107. Hammer R.E., Maika S.D., Richardson J.A., Tang J.P., Taurog J.D. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell 1990, 63:1099-1112.
108. Harkness K.A., Sussman J.D., Davies-Jones G.A., Greenwood J., Woodroofe M.N. Cytokine regulation of MCP-1 expression in brain and retinal microvascular endothelial cells. J. Neuroimmunol 2003, 142:1-9.
109. He Y., Wang J.C., Liu Y.L., Ma Z.Z., Zhu X.A., Zhang Q. Therapeutic and toxicological evaluations of cyclosporine a microspheres as a treatment vehicle for uveitis in rabbits. J. Ocul. Pharmacol. Ther. 2006, 22:121-131.
110. Heiligenhaus A., Miserocchi E., Heinz C., Gerloni V., Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology (Oxford) 2011.
111. Henderly D.E., Genstler A.J., Smith R.E., Rao N.A. Changing patterns of uveitis. Am. J. Ophthalmol. 1987, 103:131-136.
112. Herbort C.P., Rao N.A., Mochizuki M. International criteria for the diagnosis of ocular sarcoidosis: results of the first International Workshop On Ocular Sarcoidosis (IWOS). Ocul. Immunol. Inflamm. 2009, 17:160-169.
113. Hill T., Galatowicz G., Akerele T., Lau C.H., Calder V., Lightman S. Intracellular T lymphocyte cytokine profiles in the aqueous humour of patients with uveitis and correlation with clinical phenotype. Clin. Exp. Immunol. 2005, 139:132-137.
114. Hirose S., Kuwabara T., Nussenblatt R.B., Wiggert B., Redmond T.M., Gery I. Uveitis induced in primates by interphotoreceptor retinoid-binding protein. Arch. Ophthalmol. 1986, 104:1698-1702.
115. Hohki S., Ohguro N., Haruta H., Nakai K., Terabe F., Serada S., Fujimoto M., Nomura S., Kawahata H., Kishimoto T., Naka T. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp. Eye Res. 2010, 91:162-170.
116. Holland G.N. Standard diagnostic criteria for the acute retinal necrosis syndrome. Executive committee of the American Uveitis Society. Am. J. Ophthalmol. 1994, 117:663-667.
117. Hoos A., Eggermont A.M., Janetzki S., Hodi F.S., Ibrahim R., Anderson A., Humphrey R., Blumenstein B., Old L., Wolchok J. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 2010, 102:1388-1397.
118. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., Antoni C., Draelos Z., Gold M.H., Durez P., Tak P.P., Gomez-Reino J.J., Foster C.S., Kim R.Y., Samson C.M., Falk N.S., Chu D.S., Callanan D., Nguyen Q.D., Rose K., Haider A., Di Padova F. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci. Transl Med. 2010, 2:52ra72.
119. Imrie F.R., Dick A.D. Biologics in the treatment of uveitis. Curr. Opin. Ophthalmol. 2007, 18:481-486.
120. International Study Group for Behcet's Disease Criteria for diagnosis of Behcet's disease. Lancet 1990, 335:1078-1080.
121. Jabs D.A., Rosenbaum J.T., Foster C.S., Holland G.N., Jaffe G.J., Louie J.S., Nussenblatt R.B., Stiehm E.R., Tessler H., Van Gelder R.N., Whitcup S.M., Yocum D. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am. J. Ophthalmol. 2000, 130:492-513.
122. Jabs D.A., Nussenblatt R.B., Rosenbaum J.T. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am. J. Ophthalmol. 2005, 140:509-516.
123. Jaffe G.J., Yang C.S., Wang X.C., Cousins S.W., Gallemore R.P., Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology 1998, 105:46-56.
124. Jaffe G.J., Martin D., Callanan D., Pearson P.A., Levy B., Comstock T. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006, 113:1020-1027.
125. Jager A., Kuchroo V.K. Effector and regulatory T-cell subsets in autoimmunity and tissue inflammation. Scand. J. Immunol. 2010, 72:173-184.
126. Jamieson S.E., Peixoto-Rangel A.L., Hargrave A.C., Roubaix L.A., Mui E.J., Boulter N.R., Miller E.N., Fuller S.J., Wiley J.S., Castellucci L., Boyer K., Peixe R.G., Kirisits M.J., Elias Lde S., Coyne J.J., Correa-Oliveira R., Sautter M., Smith N.C., Lees M.P., Swisher C.N., Heydemann P., Noble A.G., Patel D., Bardo D., Burrowes D., McLone D., Roizen N., Withers S., Bahia-Oliveira L.M., McLeod R., Blackwell J.M. Evidence for associations between the purinergic receptor P2X(7) (P2RX7) and toxoplasmosis. Genes Immun. 2010, 11:374-383.
127. Jansen J.P., Crawford B., Bergman G., Stam W. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008, 11:956-964.
128. Johnsen-Soriano S., Sancho-Tello M., Arnal E., Diaz-Llopis M., Navea A., Miranda M., Bosch-Morell F., Romero F.J. Comparison of the acute effects of anti-TNF-alpha drugs on a uveitis experimental model. Ocul. Immunol. Inflamm. 2010, 18:208-215.
129. Juncker-Voss M., Prosl H., Lussy H., Enzenberg U., Auer H., Lassnig H., Muller M., Nowotny N. Screening for antibodies against zoonotic agents among employees of the Zoological Garden of Vienna, Schonbrunn, Austria. Berl. Munch. Tierarztl. Wochenschr. 2004, 117:404-409.
130. Kacmaz R.O., Kempen J.H., Newcomb C., Daniel E., Gangaputra S., Nussenblatt R.B., Rosenbaum J.T., Suhler E.B., Thorne J.E., Jabs D.A., Levy-Clarke G.A., Foster C.S. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010, 117:576-584.
131. Kadayifcilar S., Eldem B., Tumer B. Uveitis in childhood. J. Pediatr. Ophthalmol. Strabismus 2003, 40:335-340.
132. Kalsow C.M., Dwyer A.E. Retinal immunopathology in horses with uveitis. Ocul. Immunol. Inflamm. 1998, 6:239-251.
133. Kang E.H., Kim J.Y., Takeuchi F., Kim J.W., Shin K., Lee E.Y., Lee Y.J., Lee E.B., Park M.H., Song Y.W. Associations between the HLA-A polymorphism and the clinical manifestations of Behcet's disease. Arthritis. Res. Ther. 2011, 13, R49. PMID: 21429233.
134. Kaneko F., Tojo M., Sato M., Isogai E. The role of infectious agents in the pathogenesis of Behcet's disease. Adv. Exp. Med. Biol. 2003, 528:181-183.
135. Kaneko F., Oyama N., Yanagihori H., Isogai E., Yokota K., Oguma K. The role of streptococcal hypersensitivity in the pathogenesis of Behcet's Disease. Eur. J. Dermatol. 2008, 18:489-498.
136. Kappel P.J., Monnet D., Yu F., Brezin A.P., Levinson R.D., Holland G.N. Contrast sensitivity among patients with birdshot chorioretinopathy. Am. J. Ophthalmol. 2009, 147:351-356.
137. Kawashima H., Fujino Y., Mochizuki M. Effects of a new immunosuppressive agent, FK506, on experimental autoimmune uveoretinitis in rats. Invest. Ophthalmol. Vis. Sci. 1988, 29:1265-1271.
138. Ke Y., Jiang G., Sun D., Kaplan H.J., Shao H. Ocular regulatory T cells distinguish monophasic from recurrent autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 2008, 49:3999-4007.
139. Keino H., Watanabe T., Sato Y., Niikura M., Wada Y., Okada A.A. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res. Ther. 2008, 10:R122. Epub 2008 Oct 2013.
140. Kempen J.H., Daniel E., Gangaputra S., Dreger K., Jabs D.A., Kacmaz R.O., Pujari S.S., Anzaar F., Foster C.S., Helzlsouer K.J., Levy-Clarke G.A., Nussenblatt R.B., Liesegang T., Rosenbaum J.T., Suhler E.B. Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) Cohort Study. Ophthalmic Epidemiol. 2008, 15:47-55.
141. Kempen J.H., Ganesh S.K., Sangwan V.S., Rathinam S.R. Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis. Am. J. Ophthalmol. 2008, 146:813-818.
142. Kempen J.H., Altaweel M.M., Holbrook J.T., Jabs D.A., Sugar E.A. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am. J. Ophthalmol. 2010, 149:550-561.
143. Khairallah M. Are the Standardization of the Uveitis Nomenclature (SUN) working group criteria for codifying the site of inflammation appropriate for all uveitis problems? Limitations of the SUN working group classification. Ocul. Immunol. Inflamm. 2010, 18:2-4.
144. Khairallah M., Yahia S.B., Ladjimi A., Messaoud R., Zaouali S., Attia S., Jenzeri S., Jelliti B. Pattern of uveitis in a referral centre in Tunisia, North Africa. Eye (Lond) 2007, 21:33-39.
145. Khalifa Y., Loh A.R., Acharya N.R. Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease. Ocul. Immunol. Inflamm. 2009, 17:431-433.
146. Kim S.J., Adams N.A., Toma H.S., Belair M.L., Thorne J.E., Green W.R., Jabs D.A. Safety of intravitreal ketorolac and diclofenac: an electroretinographic and histopathologic study. Retina 2008, 28:595-605.
147. Kok H., Lau C., Maycock N., McCluskey P., Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology 2005, 112:1916.
148. Konig F., Bauer P., Brannath W. An adaptive hierarchical test procedure for selecting safe and efficient treatments. Biom J. 2006, 48:663-678.
149. Korn E.L., Freidlin B. Outcome-adaptive randomization: is it useful?. J. Clin. Oncol. 2011, 29:771-776.
150. Kotake S., de Smet M.D., Wiggert B., Redmond T.M., Chader G.J., Gery I. Analysis of the pivotal residues of the immunodominant and highly uveitogenic determinant of interphotoreceptor retinoid-binding protein. J. Immunol. 1991, 146:2995-3001.
151. Kotake S., Furudate N., Sasamoto Y., Yoshikawa K., Goda C., Matsuda H. Characteristics of endogenous uveitis in Hokkaido, Japan. Graefes Arch. Clin. Exp. Ophthalmol. 1997, 235:5-9.
152. Kotter I., Hamuryudan V., Ozturk Z.E., Yazici H. Interferon therapy in rheumatic diseases: state-of-the-art 2010. Curr. Opin. Rheumatol. 2010, 22:278-283.
153. Kilmartin D.J., Wilson D., Liversidge J., Dick A.D., Bruce J., Acheson R.W., Urbaniak S.J., Forrester J.V. Immunogenetics and clinical phenotype of sympathetic ophthalmia in British and Irish patients. Br. J. Ophthalmol. 2001, 85:281-286. PMID: 11222331.
154. Krause L., Köhler A.K., Altenburg A., Papoutsis N., Zouboulis C.C., Pleyer U., Stroux A., Foerster M.H. Ocular involvement is associated with HLA-B51 in Adamantiades-Behçet's disease. Eye 2009, 23:1182-1186. PMID: 18551141.
155. Kuo N.W., Lympany P.A., Menezo V., Lagan A.L., John S., Yeo T.K., Liyanage S., du Bois R.M., Welsh K.I., Lightman S. TNF-857T, a genetic risk marker for acute anterior uveitis. Invest. Ophthalmol. Vis. Sci. 2005, 46:1565-1571.
156. Lafuma A., Brezin A., Lopatriello S., Hieke K., Hutchinson J., Mimaud V., Berdeaux G. Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK. Pharmacoeconomics 2006, 24:193-205.
157. Lahmar I., Abou-Bacar A., Abdelrahman T., Guinard M., Babba H., Ben Yahia S., Kairallah M., Speeg-Schatz C., Bourcier T., Sauer A., Villard O., Pfaff A.W., Mousli M., Garweg J.G., Candolfi E. Cytokine profiles in toxoplasmic and viral uveitis. J. Infect. Dis. 2009, 199:1239-1249.
158. Lambe T., Leung J.C., Bouriez-Jones T., Silver K., Makinen K., Crockford T.L., Ferry H., Forrester J.V., Cornall R.J. CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions. J. Immunol. 2006, 177:3055-3062.
159. Laroni A., Calabrese M., Perini P., Albergoni M.P., Ranzato F., Tiberio M., Battistin L., Gallo P. Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. J. Neurol. 2006, 253:636-639.
160. Lau C.H., Missotten T., Salzmann J., Lightman S.L. Acute retinal necrosis features, management, and outcomes. Ophthalmology 2007, 114:756-762.
161. Lau A.W., Biester S., Cornall R.J., Forrester J.V. Lipopolysaccharide-activated IL-10-secreting dendritic cells suppress experimental autoimmune uveoretinitis by MHCII-dependent activation of CD62L-expressing regulatory T cells. J. Immunol. 2008, 180:3889-3899.
162. LeHoang P., Ozdemir N., Benhamou A., Tabary T., Edelson C., Betuel H., Semiglia R., Cohen J.H. HLA-A29.2 subtype associated with birdshot retinochoroidopathy. Am. J. Ophthalmol. 1992, 113:33-35. PMID: 1728143.
163. LeHoang P., Sterkers M., Thillaye B., de Kozak Y., Coscas G., Faure J.P. Primate model of uveoretinitis and vasculitis/experimental autoimmune uveoretinitis induced in cynomolgus monkeys by retinal s antigen. Ophthalmic Res. 2008, 40:181-188.
164. Lee P.P., Cunningham W.E., Nakazono T.T., Hays R.D. Associations of eye diseases and symptoms with self-reported physical and mental health. Am. J. Ophthalmol. 2009, 148:804-808.
165. Lee R.W., Schewitz L.P., Nicholson L.B., Dayan C.M., Dick A.D. Steroid refractory CD4+ T cells in patients with sight-threatening uveitis. Invest. Ophthalmol. Vis. Sci. 2009, 50:4273-4278.
166. Lehmacher W., Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999, 55:1286-1290.
167. Levinson R.D., Brezin A., Rothova A., Accorinti M., Holland G.N. Research criteria for the diagnosis of birdshot chorioretinopathy: results of an international consensus conference. Am. J. Ophthalmol. 2006, 141:185-187.
168. Li H., Zhang G.X., Chen Y., Xu H., Fitzgerald D.C., Zhao Z., Rostami A. CD11c+CD11b+ dendritic cells play an important role in intravenous tolerance and the suppression of experimental autoimmune encephalomyelitis. J. Immunol. 2008, 181:2483-2493.
169. Lightman S., Greenwood J. Effect of lymphocytic infiltration on the blood-retinal barrier in experimental autoimmune uveoretinitis. Clin. Exp. Immunol. 1992, 88:473-477.
170. Lightman S., McDonald W.I., Bird A.C., Francis D.A., Hoskins A., Batchelor J.R., Halliday A.M. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987, 110(Pt 2):405-414.
171. Lightman S.L., Caspers-Velu L.E., Hirose S., Nussenblatt R.B., Palestine A.G. Angiography with fluorescein-labeled dextrans in a primate model of uveitis. Arch. Ophthalmol. 1987, 105:844-848.
172. Lightman S.L., Palestine A.G., Rapoport S.I., Rechthand E. Quantitative assessment of the permeability of the rat blood-retinal barrier to small water-soluble non-electrolytes. J. Physiol. 1987, 389:483-490.
173. Lightman, S., Belfort, R., Naik, R., Lowder, C., Rentz, A., Foster, C.S., Cui, H., Whitcup, S., Kowalski, J.D.R., 2011. Vision related functioning outcomes of dexamethasone intravitreal implant for the treatment of patients with non-infectious intermediate or posterior uveitis: results of a randomized clinical trial. Manuscript in preparation.
174. Lin P., Loh A.R., Margolis T.P., Acharya N.R. Cigarette smoking as a risk factor for uveitis. Ophthalmology 2010, 117:585-590.
175. Liu Q., Proschan M.A., Pledger G.W. A unified theory of two-stage adaptive designs. J. Am. Stat. Assoc. 2002, 97:1034-1041.
176. Lobo A., Lightman S. Vitreous aspiration needle tap in the diagnosis of intraocular inflammation. Ophthalmology 2003, 110:595-599.
177. London N.J., Rathinam S.R., Cunningham E.T. The epidemiology of uveitis in developing countries. Int. Ophthalmol. Clin. 2010, 50:1-17.
178. Lopez-Gonzalez R., Loza E., Jover J.A., Benitez Del Castillo J.M., Mendez R., Hernandez-Garcia C., Pato E. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand. J. Rheumatol. 2009, 38:58-62.
179. Lowder C., Belfort R., Lightman S., Foster C.S., Robinson M.R., Schiffman R.M., Li X.Y., Cui H., Whitcup S.M. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch. Ophthalmol. 2011, 129:545-553.
180. Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., Bowman E.P., Sgambellone N.M., Chan C.C., Caspi R.R. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 2008, 205:799-810. Epub 2008 Apr 2007.
181. Luqmani R.A., Bacon P.A., Moots R.J., Janssen B.A., Pall A., Emery P., Savage C., Adu D. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994, 87:671-678.
182. Mackensen F., Becker M.D., Wiehler U., Max R., Dalpke A., Zimmermann S. QuantiFERON TB-Gold-a new test strengthening long-suspected tuberculous involvement in serpiginous-like choroiditis. Am. J. Ophthalmol. 2008, 146:761-766.
183. Mahajan V.B., Gehrs K.M., Goldstein D.A., Fischer D.H., Lopez J.S., Folk J.C. Management of sympathetic ophthalmia with the fluocinolone acetonide implant. Ophthalmology 2009, 116:552-557.
184. Malinowski S.M., Pulido J.S., Goeken N.E., Brown C.K., Folk J.C. The association of HLA-B8, B51, DR2, and multiple sclerosis in pars planitis. Ophthalmology 1993, 100:1199-1205.
185. Mangione C.M., Lee P.P., Gutierrez P.R., Spritzer K., Berry S., Hays R.D. Development of the 25-item National Eye Institute visual function questionnaire. Arch. Ophthalmol. 2001, 119:1050-1058.
186. Markomichelakis N.N., Halkiadakis I., Pantelia E., Peponis V., Patelis A., Theodossiadis P., Theodossiadis G. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology 2004, 111:946-953.
187. Markomichelakis N.N., Halkiadakis I., Pantelia E., Georgalas I., Chrysanthi K., Theodossiadis P., Moschos M., Theodossiadis G., Kouvatseas G. Course of macular edema in uveitis under medical treatment. Ocul. Immunol. Inflamm. 2007, 15:71-79.
188. Martin D.F., DeBarge L.R., Nussenblatt R.B., Chan C.C., Roberge F.G. Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J. Immunol. 1995, 154:922-927.
189. Massof R.W., Rubin G.S. Visual function assessment questionnaires. Surv. Ophthalmol. 2001, 45:531-548.
190. Mattapallil M.J., Augello A., Cheadle C., Teichberg D., Becker K.G., Chan C.C., Mattapallil J.J., Pennesi G., Caspi R.R. Differentially expressed genes in MHC-compatible rat strains that are susceptible or resistant to experimental autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 2008, 49:1957-1970.
191. Mattapallil M.J., Sahin A., Silver P.B., Sun S.H., Chan C.C., Remmers E.F., Hejtmancik J.F., Caspi R.R. Common genetic determinants of uveitis shared with other autoimmune disorders. J. Immunol. 2008, 180:6751-6759.
192. McCannel C.A., Holland G.N., Helm C.J., Cornell P.J., Winston J.V., Rimmer T.G. Causes of uveitis in the general practice of ophthalmology. UCLA community-based uveitis study group. Am. J. Ophthalmol. 1996, 121:35-46.
193. McGeachy M.J., Cua D.J. Th17 cell differentiation: the long and winding road. Immunity 2008, 28:445-453.
194. Meads C., Hyde C. What is the cost of blindness?. Br. J. Ophthalmol. 2003, 87:1201-1204.
195. Mello P.R., Roma Ade C., Moraes H.V. Analysis of the life quality of infectious and non-infectious patients with uveitis using the NEI-VFQ-25 questionnaire. Arq. Bras. Oftalmol. 2008, 71:847-854.
196. Menezo V., Lau C., Comer M., Lightman S. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin. Exp. Ophthalmol. 2005, 33:16-21.
197. Merrill P.T., Kim J., Cox T.A., Betor C.C., McCallum R.M., Jaffe G.J. Uveitis in the southeastern United States. Curr. Eye Res. 1997, 16:865-874.
198. Milia A.F., Ibba-Manneschi L., Manetti M., Benelli G., Messerini L., Matucci-Cerinic M. HLA-B27 transgenic rat: an animal model mimicking gut and joint involvement in human spondyloarthritides. Ann. N. Y. Acad. Sci. 2009, 1173:570-574.
199. Miserocchi E., Modorati G., Mosconi P., Colucci A., Bandello F. Quality of life in patients with uveitis on chronic systemic immunosuppressive treatment. Ocul. Immunol. Inflamm. 2010, 18:297-304.
200. Mitchell J., Bradley C. Quality of life in age-related macular degeneration: a review of the literature. Health Qual. Life Outcomes 2006, 4:97.
201. Miyara M., Sakaguchi S. Human FoxP3(+)CD4(+) regulatory T cells: their knowns and unknowns. Immunol. Cell Biol. 2011, 89:346-351.
202. Miyazaki A., Kitaichi N., Ohgami K., Iwata D., Jin X.H., Iwabuchi K., Morohashi T., Ohno S., Onoe K. Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats. Graefes Arch. Clin. Exp. Ophthalmol. 2008, 246:747-757.
203. Mochizuki M., Nussenblatt R.B., Kuwabara T., Gery I. Effects of cyclosporine and other immunosuppressive drugs on experimental autoimmune uveoretinitis in rats. Invest. Ophthalmol. Vis. Sci. 1985, 26:226-232.
204. Muhaya M., Calder V., Towler H.M., Shaer B., McLauchlan M., Lightman S. Characterization of T cells and cytokines in the aqueous humour (AH) in patients with Fuchs' heterochromic cyclitis (FHC) and idiopathic anterior uveitis (IAU). Clin. Exp. Immunol. 1998, 111:123-128.
205. Murphy C.C., Hughes E.H., Frost N.A., Dick A.D. Quality of life and visual function in patients with intermediate uveitis. Br. J. Ophthalmol. 2005, 89:1161-1165.
206. Murphy C.C., Greiner K., Plskova J., Frost N.A., Forrester J.V., Dick A.D. Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br. J. Ophthalmol. 2007, 91:154-156.
207. Nadkarni S., Mauri C., Ehrenstein M.R. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J. Exp. Med. 2007, 204:33-39.
208. Ni M., Chan C.C., Nussenblatt R.B., Mochizuki M. FR900506 (FK506) and 15-deoxyspergualin (15-DSG) modulate the kinetics of infiltrating cells in eyes with experimental autoimmune uveoretinitis. Autoimmunity 1990, 8:43-51.
209. Niccoli L., Nannini C., Benucci M., Chindamo D., Cassara E., Salvarani C., Cimino L., Gini G., Lenzetti I., Cantini F. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007, 46:1161-1164.
210. Noda K., Miyahara S., Nakazawa T., Almulki L., Nakao S., Hisatomi T., She H., Thomas K.L., Garland R.C., Miller J.W., Gragoudas E.S., Kawai Y., Mashima Y., Hafezi-Moghadam A. Inhibition of vascular adhesion protein-1 suppresses endotoxin-induced uveitis. FASEB J. 2008, 22:1094-1103.
211. Nomura Y., Kitteringham N., Shiba K., Goseki M., Kimura A., Mineshita S. Use of the highly sensitive PCR method to detect the Herpes simplex virus type 1 genome and its expression in samples from Behcet disease patients. J. Med. Dent Sci. 1998, 45:51-58.
212. Novartis, 2010. United States Securities and Exchange Commission Form 20-F.
213. Nussenblatt R.B. The natural history of uveitis. Int. Ophthalmol. 1990, 14:303-308.
214. Nussenblatt R.B., Mittal K.K., Ryan S., Green W.R., Maumenee A.E. Birdshot retinochoroidopathy associated with HLA-A29 antigen and immune responsiveness to retinal S-antigen. Am. J. Ophthalmol. 1982, 94:147-158.
215. Nussenblatt R.B., Palestine A.G., Chan C.C. Cyclosporine therapy for uveitis: long-term follow up. J. Ocul. Pharmacol. 1985, 1:369-382.
216. Nussenblatt R.B., Palestine A.G., Chan C.C., Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985, 92:467-471.
217. Nussenblatt R.B., Caspi R.R., Mahdi R., Chan C.C., Roberge F., Lider O., Weiner H.L. Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. J. Immunol. 1990, 144:1689-1695.
218. Nussenblatt R.B., Palestine A.G., Chan C.C., Stevens G., Mellow S.D., Green S.B. Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am. J. Ophthalmol. 1991, 112:138-146.
219. Nussenblatt R.B., Fortin E., Schiffman R., Rizzo L., Smith J., Van Veldhuisen P., Sran P., Yaffe A., Goldman C.K., Waldmann T.A., Whitcup S.M. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. Proc. Natl. Acad. Sci. U S A 1999, 96:7462-7466.
220. Ohta K., Sano K., Imai H., Kikuchi T. Cytokine and molecular analyses of intraocular lymphoma. Ocul. Immunol. Inflamm. 2009, 17:142-147.
221. Okada A.A. The dream of biologics in uveitis. Arch. Ophthalmol. 2010, 128:632-635.
222. Okhravi N., Towler H.M., Hykin P., Matheson M., Lightman S. Assessment of a standard treatment protocol on visual outcome following presumed bacterial endophthalmitis. Br. J. Ophthalmol. 1997, 81:719-725.
223. Okhravi N., Morris A., Kok H.S., Menezo V., Dowler J.G., Hykin P.G., Lightman S. Intraoperative use of intravitreal triamcinolone in uveitic eyes having cataract surgery: pilot study. J. Cataract Refract Surg. 2007, 33:1278-1283.
224. Ooi K.G., Galatowicz G., Calder V.L., Lightman S.L. Cytokines and chemokines in uveitis: is there a correlation with clinical phenotype?. Clin. Med. Res. 2006, 4:294-309.
225. Oruc S., Duffy B.F., Mohanakumar T., Kaplan H.J. The association of HLA class II with pars planitis. Am. J. Ophthalmol. 2001, 131:657-659. PMID: 11336946.
226. Oruc S., Kaplan A.D., Galen M., Kaplan H.J. Uveitis referral pattern in a Midwest University eye center. Ocul. Immunol. Inflamm. 2003, 11:287-298.
227. Paire V., Lebreton O., Weber M. Effectiveness of interferon alpha in the treatment of uveitis macular edema refractory to corticosteroid and/or immunosuppressive treatment. J. Fr. Ophtalmol 2010, 33:152-162.
228. Paroli M.P., Teodori C., D'Alessandro M., Mariani P., Iannucci G., Paroli M. Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis. Eur. J. Ophthalmol. 2007, 17:938-942.
229. Pasadhika S., Kempen J.H., Newcomb C.W., Liesegang T.L., Pujari S.S., Rosenbaum J.T., Thorne J.E., Foster C.S., Jabs D.A., Levy-Clarke G.A., Nussenblatt R.B., Suhler E.B. Azathioprine for ocular inflammatory diseases. Am. J. Ophthalmol. 2009, 148:500-509.
230. Pearson P.A., Jaffe G.J., Martin D.F., Cordahi G.J., Grossniklaus H., Schmeisser E.T., Ashton P. Evaluation of a delivery system providing long-term release of cyclosporine. Arch. Ophthalmol. 1996, 114:311-317.
231. Perez-Guijo V., Santos-Lacomba M., Sanchez-Hernandez M., Castro-Villegas Mdel C., Gallardo-Galera J.M., Collantes-Estevez E. Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. Curr. Med. Res. Opin. 2004, 20:155-157.
232. Perkins E.S., Folk J. Uveitis in London and Iowa. Ophthalmologica 1984, 189:36-40.
233. Potter A.R. Causes of blindness and visual handicap in the Central African Republic. Br. J. Ophthalmol. 1991, 75:326-328.
234. Prijyanonda B., Bovornkitti S., Thianprasit M., Mettiyawongse S., Chantarakul N., Chaturongkul S., Senapadung S., Payanand V., Paranasi U. Epidemiological study of histoplasmosis in Thailand. XX. A survey in Nakornrajsima Province. J. Med. Assoc. Thai 1970, 53:110-116.
235. Pujari S.S., Kempen J.H., Newcomb C.W., Gangaputra S., Daniel E., Suhler E.B., Thorne J.E., Jabs D.A., Levy-Clarke G.A., Nussenblatt R.B., Rosenbaum J.T., Foster C.S. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010, 117:356-365.
236. Pulido J.S., Pulido J.E., Michet C.J., Vile R.G. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina 2010, 30:1-5.
237. Pye C.C. Uveodermatologic syndrome in an Akita. Can. Vet. J. 2009, 50:861-864.
238. Rajagopal R., Harbour J.W. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina 2011, 31:435-440.
239. Rathinam S.R., Cunningham E.T. Infectious causes of uveitis in the developing world. Int. Ophthalmol. Clin. 2000, 40:137-152.
240. Read R.W., Holland G.N., Rao N.A., Tabbara K.F., Ohno S., Arellanes-Garcia L., Pivetti-Pezzi P., Tessler H.H., Usui M. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am. J. Ophthalmol. 2001, 131:647-652.
241. Remmers E.F., Cosan F., Kirino Y., Ombrello M.J., Abaci N., Satorius C., Le J.M., Yang B., Korman B.D., Cakiris A., Aglar O., Emrence Z., Azakli H., Ustek D., Tugal-Tutkun I., Akman-Demir G., Chen W., Amos C.I., Dizon M.B., Kose A.A., Azizlerli G., Erer B., Brand O.J., Kaklamani V.G., Kaklamanis P., Ben-Chetrit E., Stanford M., Fortune F., Ghabra M., Ollier W.E., Cho Y.H., Bang D., O'Shea J., Wallace G.R., Gadina M., Kastner D.L., Gül A. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat. Genet. 2010, 42:698-702. PMID: 20622878.
242. Robinson R., Deutsch J., Jones H.S., Youngson-Reilly S., Hamlin D.M., Dhurjon L., Fielder A.R. Unrecognised and unregistered visual impairment. Br. J. Ophthalmol. 1994, 78:736-740.
243. Rodriguez A., Calonge M., Pedroza-Seres M., Akova Y.A., Messmer E.M., D'Amico D.J., Foster C.S. Referral patterns of uveitis in a tertiary eye care center. Arch. Ophthalmol. 1996, 114:593-599.
244. Ronday M.J., Stilma J.S., Barbe R.F., McElroy W.J., Luyendijk L., Kolk A.H., Bakker M., Kijlstra A., Rothova A. Aetiology of uveitis in Sierra Leone, west Africa. Br. J. Ophthalmol. 1996, 80:956-961.
245. Rosenbaum J.T., Wernick R. Selection and interpretation of laboratory tests for patients with uveitis. Int. Ophthalmol. Clin. 1990, 30:238-243.
246. Rosenbaum J.T., Wernick R. The utility of routine screening of patients with uveitis for systemic lupus erythematosus or tuberculosis. A Bayesian analysis. Arch. Ophthalmol. 1990, 108:1291-1293.
247. Rothe Nissen K., Sjolie A.K., Jensen H., Borch-Johnsen K., Rosenberg T. The prevalence and incidence of visual impairment in people of age 20-59 years in industrialized countries: a review. Ophthalmic Epidemiol. 2003, 10:279-291.
248. Rothova A., Buitenhuis H.J., Meenken C., Brinkman C.J., Linssen A., Alberts C., Luyendijk L., Kijlstra A. Uveitis and systemic disease. Br. J. Ophthalmol. 1992, 76:137-141.
249. Rothova A., Suttorp-van Schulten M.S., Frits Treffers W., Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br. J. Ophthalmol. 1996, 80:332-336.
250. Saari K.M., Paivonsalo-Hietanen T., Vaahtoranta-Lehtonen H., Tuominen J., Sillanpaa M. Epidemiology of endogenous uveitis in south-western Finland. Acta Ophthalmol. Scand. 1995, 73:345-349.
251. Sadreddini S., Noshad H., Molaeefard M., Noshad R. Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod. Rheumatol. 2008, 18:306-308.
252. Sallam A., Comer R.M., Chang J.H., Grigg J.R., Andrews R., McCluskey P.J., Lightman S. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch. Ophthalmol. 2008, 126:200-205.
253. Sallam A., Sheth H.G., Habot-Wilner Z., Lightman S. Outcome of raised intraocular pressure in uveitic eyes with and without a corticosteroid-induced hypertensive response. Am. J. Ophthalmol. 2009, 148:207-213.
254. Sartani G., Silver P.B., Rizzo L.V., Chan C.C., Wiggert B., Mastorakos G., Caspi R.R. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest. Ophthalmol. Vis. Sci. 1996, 37:2211-2218.
255. Sato H., Woodhead F.A., Ahmad T., Grutters J.C., Spagnolo P., van den Bosch J.M., Maier L.A., Newman L.S., Nagai S., Izumi T., Wells A.U., du Bois R.M., Welsh K.I. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Hum. Mol. Genet. 2010, 19:4100-4111. PMID: 20685690.
256. Schiffman R.M., Jacobsen G., Whitcup S.M. Visual functioning and general health status in patients with uveitis. Arch. Ophthalmol. 2001, 119:841-849.
257. Schulman J.A., Liang C., Kooragayala L.M., King J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003, 110:437-442.
258. Shu Q., Yang P., Hou S., Li F., Chen Y., Du L., Jiang Z. Interleukin-17 gene polymorphism is associated with Vogt-Koyanagi-Harada syndrome but not with Behçet's disease in a Chinese Han population. Hum. Immunol. 2010, 71:988-991.
259. Shukla D., Behera U.C., Chakraborty S., Mahalakshmi R., Prasad N.M. Serous macular detachment as a predictor of resolution of macular edema with intravitreal triamcinolone injection. Ophthalmic Surg. Lasers Imaging 2009, 40:115-119.
260. Sivaprasad S., Ikeji F., Xing W., Lightman S. Tomographic assessment of therapeutic response to uveitic macular oedema. Clin. Exp. Ophthalmol. 2007, 35:719-723.
261. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., Verjee S.S., Jones L.A., Hershberg R.M. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 2006, 24:3089-3094.
262. Smit R.L., Baarsma G.S., de Vries J. Classification of 750 consecutive uveitis patients in the Rotterdam Eye Hospital. Int. Ophthalmol. 1993, 17:71-76.
263. Smith J.R., Levinson R.D., Holland G.N., Jabs D.A., Robinson M.R., Whitcup S.M., Rosenbaum J.T. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001, 45:252-257.
264. Smith J.A., Mackensen F., Sen H.N., Leigh J.F., Watkins A.S., Pyatetsky D., Tessler H.H., Nussenblatt R.B., Rosenbaum J.T., Reed G.F., Vitale S., Smith J.R., Goldstein D.A. Epidemiology and course of disease in childhood uveitis. Ophthalmology 2009, 116:1544-1551.
265. Sobaci G., Erdem U., Durukan A.H., Erdurman C., Bayer A., Koksal S., Karagul S., Bayraktar M.Z. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behcet's uveitis refractory to conventional treatments. Ophthalmology 2010, 117:1430-1435.
266. Sobrin L., Lam B.L., Liu M., Feuer W.J., Davis J.L. Electroretinographic monitoring in birdshot chorioretinopathy. Am. J. Ophthalmol. 2005, 140:52-64.
267. Soheilian M., Rabbanikhah Z., Ramezani A., Kiavash V., Yaseri M., Peyman G.A. Bevacizumab vs. triamcinolone. Ophthalmology 2010, 117:855.
268. Spagnolo P., Sato H., Marshall S.E., Antoniou K.M., Ahmad T., Wells A.U., Ahad M.A., Lightman S., du Bois R.M., Welsh K.I. Association between heat shock protein 70/Hom genetic polymorphisms and uveitis in patients with sarcoidosis. Invest. Ophthalmol. Vis. Sci. 2007, 48:3019-3025.
269. Stanford M.R., Vaughan R.W., Kondeatis E., Chen Y., Edelsten C.E., Graham E.M., Wallace G.R. Are cytokine gene polymorphisms associated with outcome in patients with idiopathic intermediate uveitis in the United Kingdom?. Br. J. Ophthalmol. 2005, 89:1013-1016.
270. Sugita S., Takase H., Taguchi C., Mochizuki M. The role of soluble TNF receptors for TNF-alpha in uveitis. Invest. Ophthalmol. Vis. Sci. 2007, 48:3246-3252.
271. Sugita S., Yamada Y., Kaneko S., Horie S., Mochizuki M. Induction of regulatory T cells by infliximab in Behcet's disease. Invest. Ophthalmol. Vis. Sci. 2011, 52:476-484.
272. Suhler E.B., Smith J.R., Wertheim M.S., Lauer A.K., Kurz D.E., Pickard T.D., Rosenbaum J.T. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch. Ophthalmol. 2005, 123:903-912.
273. Suhler E.B., Smith J.R., Giles T.R., Lauer A.K., Wertheim M.S., Kurz D.E., Kurz P.A., Lim L., Mackensen F., Pickard T.D., Rosenbaum J.T. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch. Ophthalmol. 2009, 127:819-822.
274. Suttorp-Schulten M.S., Rothova A. The possible impact of uveitis in blindness: a literature survey. Br. J. Ophthalmol. 1996, 80:844-848.
275. Suttorp-Schulten M.S., Zaal M.J., Luyendijk L., Bos P.J., Kijlstra A., Rothova A. Aqueous chamber tap and serology in acute retinal necrosis. Am. J. Ophthalmol. 1989, 108:327-328.
276. Szpak Y., Vieville J.C., Tabary T., Naud M.C., Chopin M., Edelson C., Cohen J.H., Dausset J., de Kozak Y., Pla M. Spontaneous retinopathy in HLA-A29 transgenic mice. Proc. Natl. Acad. Sci. U S A 2001, 98:2572-2576.
277. Taban M., Lowder C.Y., Kaiser P.K. Outcome of fluocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. Retina 2008, 28:1280-1288.
278. Takase H., Futagami Y., Yoshida T., Kamoi K., Sugita S., Imai Y., Mochizuki M. Cytokine profile in aqueous humor and sera of patients with infectious or noninfectious uveitis. Invest. Ophthalmol. Vis. Sci. 2006, 47:1557-1561.
279. Takase H., Sugita S., Taguchi C., Imai Y., Mochizuki M. Capacity of ocular infiltrating T helper type 1 cells of patients with non-infectious uveitis to produce chemokines. Br. J. Ophthalmol. 2006, 90:765-768.
280. Tanriverdi N., Taskintuna Duru C., Ozdal P., Ortac S., Firat E. Health-related quality of life in Behcet patients with ocular involvement. Jpn. J. Ophthalmol. 2003, 47:85-92.
281. Tao Y., Jonas J.B. Intravitreal triamcinolone. Ophthalmologica 2011, 225:1-20.
282. Tappeiner C., Heinz C., Specker C., Heiligenhaus A. Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res. 2007, 39:184-186.
283. Taylor H.R., Keeffe J.E. World blindness: a 21st century perspective. Br. J. Ophthalmol. 2001, 85:261-266.
284. Taylor S.R., Habot-Wilner Z., Pacheco P., Lightman S.L. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009, 116:797-801.
285. Taylor S.R., Salama A.D., Joshi L., Pusey C.D., Lightman S.L. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum. 2009, 60:1540-1547.
286. Terrada C., Fisson S., De Kozak Y., Kaddouri M., Lehoang P., Klatzmann D., Salomon B.L., Bodaghi B. Regulatory T cells control uveoretinitis induced by pathogenic Th1 cells reacting to a specific retinal neoantigen. J. Immunol. 2006, 176:7171-7179.
287. Tiercy J.M., Rathinam S.R., Gex-Fabry M., Baglivo E. A shared HLA-DRB1 epitope in the DR beta first domain is associated with Vogt-Koyanagi-Harada syndrome in Indian patients. Mol. Vis. 2010, 16:353-358. PMID: 20216938.
288. Tojo M., Zheng X., Yanagihori H., Oyama N., Takahashi K., Nakamura K., Kaneko F. Detection of herpes virus genomes in skin lesions from patients with Behcet's disease and other related inflammatory diseases. Acta Derm Venereol. 2003, 83:124-127.
289. Touma Z., Farra C., Hamdan A., Shamseddeen W., Uthman I., Hourani H., Arayssi T. TNF polymorphisms in patients with Behcet disease: a meta-analysis. Arch. Med. Res. 2010, 41:142-146.
290. Tran V.T., Auer C., Guex-Crosier Y., Pittet N., Herbort C.P. Epidemiological characteristics of uveitis in Switzerland. Int. Ophthalmol. 1994, 18:293-298.
291. Tran T.H., de Smet M.D., Bodaghi B., Fardeau C., Cassoux N., Lehoang P. Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. Br. J. Ophthalmol. 2008, 92:922-927.
292. Tugal-Tutkun I. Behcet disease in the developing world. Int. Ophthalmol. Clin. 2010, 50:87-98.
293. Tugal-Tutkun I., Herbort C.P., Khairallah M. Scoring of dual fluorescein and ICG inflammatory angiographic signs for the grading of posterior segment inflammation (dual fluorescein and ICG angiographic scoring system for uveitis). Int. Ophthalmol. 2010, 30:539-552.
294. Van Gelder R.N. Has the polymerase chain reaction come of age for ophthalmology?. Am. J. Ophthalmol. 2009, 147:5-7.
295. van der Wilt G.J., Groenewoud H., van Riel P. Bridging the gap between aggregate data and individual patient management: a Bayesian approach. Int. J. Technol. Assess. Health Care 2011, 27:133-138.
296. Vasconcelos-Santos D.V., Rao P.K., Davies J.B., Sohn E.H., Rao N.A. Clinical features of tuberculous serpiginous like choroiditis in contrast to classic serpiginous choroiditis. Arch. Ophthalmol. 2010, 128:853-858.
297. Venkataraman A., Rathinam S.R. A pre- and post-treatment evaluation of vision-related quality of life in uveitis. Indian J. Ophthalmol. 2008, 56:307-312.
298. Wakabayashi T., Morimura Y., Miyamoto Y., Okada A.A. Changing patterns of intraocular inflammatory disease in Japan. Ocul. Immunol. Inflamm. 2003, 11:277-286.
299. Wakefield D., Herbort C.P., Tugal-Tutkun I., Zierhut M. Controversies in ocular inflammation and immunology laser flare photometry. Ocul. Immunol. Inflamm. 2010, 18:334-340.
300. Wallace D.J., Stohl W., Furie R.A., Lisse J.R., McKay J.D., Merrill J.T., Petri M.A., Ginzler E.M., Chatham W.W., McCune W.J., Fernandez V., Chevrier M.R., Zhong Z.J., Freimuth W.W. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009, 61:1168-1178.
301. Wang J., Lu H., Hu X., Chen W., Xu Z., Li S., Xu Y. Nuclear factor translocation and acute anterior uveitis. Mol. Vis. 2011, 17:170-176.
302. Wee R., Papaliodis G. Genetics of birdshot chorioretinopathy. Semin. Ophthalmol. 2008, 23:53-57.
303. Woo P. The cytokine network in juvenile chronic arthritis. Rheum. Dis. Clin. North Am. 1997, 23:491-498.
304. Wu L., Arevalo J.F., Berrocal M.H., Maia M., Roca J.A., Morales-Canton V., Alezzandrini A.A., Diaz-Llopis M.J. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to branch retinal vein occlusions: results of the Pan American Collaborative Retina Study Group at 24 months. Retina 2009, 29:1396-1403.
305. Yamaki K., Kondo I., Nakamura H., Miyano M., Konno S., Sakuragi S. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp. Eye Res. 2000, 71:361-369.
306. Yamaki K., Takiyama N., Itho N., Mizuki N., Seiya M., Sinsuke W., Hayakawa K., Kotani T. Experimentally induced Vogt-Koyanagi-Harada disease in two Akita dogs. Exp. Eye Res. 2005, 80:273-280.
307. Yeo T.K., Ahad M.A., Kuo N.W., Spagnolo P., Menezo V., Lympany P., Lightman S. Chemokine gene polymorphisms in idiopathic anterior uveitis. Cytokine 2006, 35:29-35.
308. Young S., Larkin G., Branley M., Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Exp. Ophthalmol. 2001, 29:2-6.
309. Zamecki K.J., Jabs D.A. HLA typing in uveitis: use and misuse. Am. J. Ophthalmol. 2010, 149:189-193.
310. Zamiri P., Boyd S., Lightman S. Uveitis in the elderly-is it easy to identify the masquerade?. Br. J. Ophthalmol. 1997, 81:827-831.
311. Zein G., Berta A., Foster C.S. Multiple sclerosis-associated uveitis. Ocul. Immunol. Inflamm. 2004, 12:137-142.